BI 3802876

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyLiver Cirrhosis

Phase 1

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

CompletedNCT06081530

Boehringer IngelheimHealthy

Start: 2023-10-27End: 2025-03-20Updated: 2025-04-09

Phase 2

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

RecruitingNCT07325526

Boehringer IngelheimLiver Cirrhosis

Start: 2026-02-27End: 2027-08-05Target: 30Updated: 2026-09-01